Hydroquinidine therapy significantly increased the mean temporal burden of ST-segment elevation by 9.4 min/hour compared to baseline in patients with Brugada Syndrome.
Observational (n=10)
No
Does Hydroquinidine affect the burden of ST-segment elevation on 12-lead Holter monitoring in patients with Brugada Syndrome?
In a small pilot study of patients with Brugada Syndrome, Hydroquinidine unexpectedly increased the burden of ST-segment elevation on Holter monitoring and was associated with proarrhythmia in one patient.
Effect estimate: Mean difference 9.4 (95% CI 1.0-17.9)
Absolute Event Rate: 41% vs 31.6%
p-value: p=0.029
Chiswell et al. (Fri,) conducted a observational in Brugada Syndrome (n=10). Hydroquinidine vs. Baseline (pre-treatment) was evaluated on Mean temporal burden of ST-segment elevation (min/hr) (Mean difference 9.4, 95% CI 1.0-17.9, p=0.029). Hydroquinidine therapy significantly increased the mean temporal burden of ST-segment elevation by 9.4 min/hour compared to baseline in patients with Brugada Syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: